SINOVAC Launches "Laifu Initiative" with 69 Global Partners to Strengthen Biopharmaceutical Ecosystem Resilience

BEIJING, Aug. 29, 2025 — Sinovac Biotech Ltd. ("SINOVAC" or the "Company"), a leading global provider of biopharmaceutical products, hosted the 2025 Supply Chain Eco-Conference at the newly inaugurated SINOVAC Laifu City campus in Beijing. During the event, SINOVAC and 69 strategic partners jointly released the Laifu Initiative, a strategic roadmap designed to catalyze innovation and strengthen the resilience of the global biopharmaceutical ecosystem.

The conference convened key executives from global industry leaders including Thermo Fisher Scientific, Danaher Corporation, Cytiva, Truking Technology, WEGO, and Cobetter. The conference focused on accelerating upstream and downstream collaboration to address evolving challenges in the global healthcare landscape.

The Four Pillars of the Laifu Initiative

1. Advancing Two-Way Openness: Encouraging global partners to participate in China's healthcare development while supporting Chinese enterprises in expanding high-quality products and services to international markets.

2. Accelerating R&D Breakthroughs: Establishing joint research platforms to overcome technical bottlenecks, share innovation outcomes, and secure a competitive edge in next-generation biopharmaceutical technologies.

3. Integrating the Full Value Chain: Transitioning from traditional procurement models to deep strategic integration across R&D, manufacturing, and quality control to enhance supply chain stability and risk resilience.

4. Commitment to Quality and Operational Excellence: Adhering to the highest global quality standards while optimizing processes and resources to achieve cost-efficiency and sustainable, multi-party growth.

In his keynote address, Mr. Yin Weidong, Chairman, President, and CEO of SINOVAC, highlighted fourtransformative trends reshaping the industry: the universal application of biotechnology, the convergence of AI and biotech, shifting geopolitical landscapes, and the role of China's 1.4-billion-person domestic market as a robust anchor for global engagement.

In the face of these four trends in the landscape, Mr. Yin believes that the true way forward for China's biopharmaceutical industry is to provide a "Global Solution" for human health meeting new health needs with the best services and scientific products, winning the trust of more countries through the highest quality standards, and ensuring vaccines are affordable and accessible to more people through maximum production volume and minimum cost.

The event featured 14 partners presenting innovations in raw materials, laboratory equipment, and quality control solutions.

Driven by innovation and global synergy, the Chinese biopharmaceutical industry has transitioned from a follower to a strategic partner on the global stage. SINOVAC remains committed to deep-level collaboration as the definitive pathway to addressing global health challenges and achieving sustainable growth.

About SINOVAC

Sinovac Biotech Ltd. (SINOVAC) is a global biopharmaceutical company headquartered in China. Guided by its mission to “Supply Vaccines to Eliminate Human Diseases,” the Company is dedicated to the research, development, manufacturing and supply of vaccines and related biological products, providing vaccine products and related solutions for disease prevention and control worldwide.

SINOVAC has a diversified vaccine portfolio across multiple disease areas, including influenza, viral hepatitis, varicella, hand, foot and mouth disease (HFMD), poliomyelitis, rabies, tetanus, and pneumococcal disease. Three of SINOVAC's vaccines have been prequalified by the World Health Organization: the inactivated hepatitis A vaccine Healive®, the Sabin-strain inactivated poliomyelitis  vaccine (sIPV), and the live attenuated varicella vaccine.

SINOVAC has extensive experience in vaccine research, development and commercialization for emerging infectious diseases and public health emergencies. The Company initiated vaccine R&D in response to major public health threats, including SARS, H5N1, H1N1, and COVID-19, and developed the world's first inactivated SARS vaccine (with Phase I clinical trials completed), China's first inactivated pandemic influenza vaccine against H5N1 (Panflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the world's most widely used inactivated COVID-19 vaccine. Beyond its marketed portfolio, SINOVAC continues to advance its R&D pipeline, spanning combination vaccines, recombinant protein vaccines, mRNA technologies, antibody-based products, and other next-generation technologies and product platforms, while expanding its capabilities in disease prevention and biopharmaceuticals.

With a long-standing commitment to innovation and global health, SINOVAC continues to deepen collaboration with research institutions, international organizations, and local partners while expanding its global presence. Through technological collaboration, localized production, and industrial partnerships, the Company aims to improve access to high-quality vaccines across regions, better address local disease prevention and healthcare needs, and strengthen preparedness for future public health challenges.

For more information, please see the Company's website at www.sinovac.com.